

To: [REDACTED]@minvws.nl; [REDACTED]@minvws.nl; [REDACTED] ([REDACTED]@minez.nl); [REDACTED]@minez.nl; [REDACTED]
[REDACTED]@minaz.nl]
From: [REDACTED]
Sent: Mon 1/25/2021 12:33:18 PM
Subject: Update from MSD [Vertrouwelijk-Confidential]
Received: Mon 1/25/2021 12:33:26 PM

Vertrouwelijk-Confidential

Dear [REDACTED]

I am aware that we have had a number of conversations both recently and over the last few months regarding the rapid investment of MSD into a pipeline of vaccines and treatments targeting COVID19 / SARS-CoV-2.

It is with disappointment that I write to inform you today that following the review of results from our phase 1 trials MSD will be discontinuing the development of our 2 vaccines candidates V590 and V591. The decision has been taken to focus our efforts to advance our clinical programmes on two therapeutic candidates MK-4482 and MK7110. As I indicated to you, I look forward to providing more information on the status and timelines associated with these treatments shortly.

I have very much valued the engagement and communication that you and your teams have offered over this time, as we have heavily invested here in The Netherlands to accelerate these programmes, at risk our own risk. I hope we can continue to maintain open lines of communication in the interests of providing you with all the relevant information as you and your teams continue to manage this pandemic. If you should like any further information please feel free to come back to me.

In the meantime I wish you every success in your leadership of the continued response.

Your sincerely

[REDACTED]

[REDACTED]

MSD BV

[REDACTED]

[Waarderweg 39](#), 2031 BN Haarlem, The Netherlands
P.O. Box 581, 2003 PC Haarlem, The Netherlands

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (2000 Galloping Hill Road, Kenilworth, New Jersey, USA 07033), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html> that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.